uniQure N.V. (QURE:NASDAQ) closed at $22.71 on November 10, 2026, down 0.35% on the day. The stock trades 56.1% below its 52-week high of $51.72 and 160.1% above its 52-week low of $8.73. Over the past year, it lost 12.8%. uniQure N.V. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, QURE closed higher on 115 days (46%). Its best day was June 17, 2026 (+78.44%) and its worst was September 29, 2026 (-37.33%). The stock moved 10% or more in a single session 21 times. It opened at least 5% above the previous day's high 5 times.
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Find more stocks like QURE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.